Spray drying formulation of albendazole microspheres by experimental design. In vitro - In vivo studies

Drug Development and Industrial Pharmacy

Volumn 41, Issue 2, 2015, Pages 244-252

  García, Agustina ^a,b   Leonardi, Darío ^a,b   Piccirilli, Gisela N ^a,b   Mamprin, María E ^b   Olivieri, Alejandro C ^a,b   Lamas, María C ^a,b  

^a Universidad Nacional de Rosario   (Argentina)

^b UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

Author keywords

Albendazole; Biomaterials; Microspheres; Oral drug release; Spray drying

Indexed keywords

ALBENDAZOLE; CARBOXYMETHYLCELLULOSE; CHITOSAN; MICROSPHERE; PECTIN;

ANIMAL EXPERIMENT; ANTHELMINTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; ENCAPSULATION; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; RAT; REPRODUCIBILITY; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG STABILITY; MALE; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PROCEDURES; WISTAR RAT;

ADMINISTRATION, ORAL; ALBENDAZOLE; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARBOXYMETHYLCELLULOSE SODIUM; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DRUG DELIVERY SYSTEMS; DRUG STABILITY; IN VITRO TECHNIQUES; MALE; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; PECTINS; RATS; RATS, WISTAR;

EID: 84921909744     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2013.858737     Document Type: Article

References (44)

1. Herrero EP, Valle EMMD, Galán MA. Development of a new technology for the production of microcapsules based in atomization processes. Chem Eng J 2006;117:137-42.
2. Sandri G, Bonferoni MC, Chetoni P, et al. Ophthalmic delivery systems based on drug-polymer-polymer ionic ternary interaction: in vitro and in vivo characterization. Eur J Pharm Biopharm 2006; 62:59-69.
3. Quinteros DA, Rigo VR, Kairuz AFJ, et al. Interaction between a cationic polymethacrylate (Eudragit E100) and anionic drugs. Eur J Pharm Sci 2008;33:72-9.
4. Lankalapalli S, Kolapalli RM. Biopharmaceutical evaluation of diclofenac sodium controlled release tablets prepared from gum karaya-chitosan polyelectrolyte complexes. Drug Dev Ind Pharm 2012;38:815-24.
5. Wang FQ, Li P, Zhang JP, et al. A novel pH-sensitive magnetic alginate-chitosan beads for albendazole delivery. Drug Dev Ind Pharm 2010;36:867-77.
6. Liu YH, Zhu X, Zhou D, et al. pH-sensitive and mucoadhesive microspheres for duodenum-specific drug delivery system. Drug Dev Ind Pharm 2011;37:868-74.
7. Rozenberg BA, Tenne R. Polymer-assisted fabrication of nanoparticles and nanocomposites. Prog Polym Sci 2008;33:40-112.
8. Dreve S, Kacso I, Popa A, et al. Structural investigation of chitosanbased microspheres with some anti-inflammatory drugs. J Mol Struct 2011;997:78-86.
9. Lu Z, Chen W, Hamman JH. Chitosan-polycarbophil interpolyelectrolyte complex as a matrix former for controlled release of poorly water-soluble drugs I: in vitro evaluation. Drug Dev Ind Pharm 2010;36:539-46.
10. El-Gibaly I, Meki AMA, Abdel-Ghaffar SK. Novel B melatoninloaded chitosan microcapsules: in vitro characterization and antiapoptosis efficacy for aflatoxin B1-induced apoptosis in rat liver. Int J Pharm 2003;260:5-22.
11. Zhang Y, Wei W, Lv P, et al. Preparation and evaluation of alginate-chitosan microspheres for oral delivery of insulin. Eur J Pharm Biopharm 2011;77:11-19.
12. Xu Q, Xia Y, Wang C-H, Pack DW. Monodisperse double-walled microspheres loaded with chitosan-p53 nanoparticles and doxorubicin for combined gene therapy and chemotherapy. J Control Release 2012;163:130-5.
13. Pillai CKS, Paul W, Sharma CP. Chitin and chitosan polymers: chemistry, solubility and fiber formation. Prog Polym Sci 2009;34: 641-78.
14. Kasaai MR. A review of several reported procedures to determine the degree of N-acetylation for chitin and chitosan using infrared spectroscopy. Carbohyd Polym 2008;71:497-508.
15. Liu Y, Tang J, Chen X, Xin JH. A templating route to nanoporous chitosan materials. Carbohyd Res 2005;340:2816-20.
16. Felt O, Buri P, Gurny R. Chitosan: a unique polysaccharide for drug delivery. Drug Dev Ind Pharm 1998;24:979-93.
17. Marudova M, Lang S, Brownsey GJ, Ring SG. Pectin-chitosan multilayer formation. Carbohydr Res 2005;340:2144-9.
18. Marudova M, MacDougall AJ, Ring SG. Pectin-chitosan interactions and gel formation. Carbohydr Res 2004;339:1933-9.
19. Lin Y, Chen Q, Luo H. Preparation and characterization of N-(2- carboxybenzyl)chitosan as a potential pH-sensitive hydrogel for drug delivery. Carbohyd Res 2007;342:87-95.
20. Zambito Y, Di Colo G. Preparation and in vitro evaluation of chitosan matrices for colonic controlled drug delivery. J Pharm Pharm Sci 2003;6:274-81.
21. Yu CY, Yin BC, Zhang W, et al. Composite microparticle drug delivery systems based on chitosan, alginate and pectin with improved pH-sensitive drug release property. Colloid Surface B 2009;68:245-9.
22. Kas HS. Chitosan: properties, preparations and application to microparticulate systems. J Microencapsul 1997;14:689-711.
23. Itoh K, Hirayama T, Takahashi A, et al. In situ gelling pectin formulations for oral drug delivery at high gastric pH. Int J Pharm 2007;335:90-6.
24. Gómez-Burgaz M, García-Ochoa B, Torrado-Santiago S. Chitosan-carboxymethylcellulose interpolymer complexes for gastric-specific delivery of clarithromycin. Int J Pharm 2008;359:135-43.
25. Lü S, Liu M, Ni B. An injectable oxidized carboxymethylcellulose/N-succinyl-chitosan hydrogel system for protein delivery. Chem Eng J 2010;160:779-87.
26. Kawabata Y, Wada K, Nakatani M, et al. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm 2011;420:1-10.
27. Castillo JA, Palomo-Canales J, Garcia JJ, et al. Preparation and characterization of albendazole beta-cyclodextrin complexes. Drug Dev Ind Pharm 1999;25:1241-8.
28. Dayan AD. Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop 2003;86: 141-59.
29. Vogt M, Kunath K, Dressman JB. Dissolution improvement of four poorly water soluble drugs by cogrinding with commonly used excipients. Eur J Pharm Biopharm 2008;68:330-7.
30. Simi SP, Saraswathi R, Sankar C, et al. Formulation and evaluation of albendazole microcapsules for colon delivery using chitosan. Asian Pac J Trop Med 2010;3:374-8.
31. Daniel-Mwambete K, Torrado S, Cuesta-Bandera C, et al. The effect of solubilization on the oral bioavailability of three benzimidazole carbamate drugs. Int J Pharm 2004;272:29-36.
32. Sinha VR, Singla AK, Wadhawan S, et al. Chitosan microspheres as a potential carrier for drugs. Int J Pharm 2004;274:1-33.
33. Stulzer HK, Tagliari MP, Parize AL, et al. Evaluation of cross-linked chitosan microparticles containing acyclovir obtained by spraydrying. Mater Sci Eng B 2009;29:387-92.
34. Lee J-S, Kim JS, Lee HG. g-Oryzanol-loaded calcium pectinate microparticles reinforced with chitosan: optimization and release characteristics. Colloid Surface B 2009;70:213-17.
35. Leonardi D, Lamas MC, Olivieri AC. Multiresponse optimization of the properties of albendazole-chitosan microparticles. J Pharm Biomed Anal 2008;48:802-7.
36. Swain S, Behera UA, Beg S, et al. Design and characterization of enteric-coated controlled release mucoadhesive microcapsules of Rabeprazole sodium. Drug Dev Ind Pharm 2013;39:548-60.
37. Piccirilli G, García A, Leonardi D, et al. Chitosan microparticles: influence of the gelation process on the release profile and oral bioavailability of albendazole, a class II compound. Drug Dev Ind Pharm 2013. [Epub ahead of print]. doi:10.3109/03639045.2013.829486.
38. European Pharmacopoeia. 8th ed. Strasbourg, France; 2013.
39. Tansel B, Nagarajan P. SEM study of phenolphthalein adsorption on granular activated carbon. Adv Environ Res 2004;8:411-15.
40. Adami R, Reverchon E. Composite polymer-Fe3O4 microparticles for biomedical applications, produced by Supercritical Assisted Atomization. Powder Technol 2012;218:102-8.
41. Singh I, Kumar P. Preformulation studies for direct compression suitability of cefuroxime axetil and paracetamol: a graphical representation using SeDeM diagram. Acta Pol Pharm 2012;69: 87-93.
42. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123-33.
43. Dib A, Palma S, Suarez G, et al. Albendazole sulphoxide kinetic disposition after treatment with different formulations in dogs. J Vet Pharmacol Ther 2011;34:136-41.
44. Kitzman D, Cheng KJ, Fleckenstein L. HPLC assay for albendazole and metabolites in human plasma for clinical pharmacokinetic studies. J Pharm Biomed Anal 2002;30: 801-13.